More about... medical virology : Human papillomavirus (HPV)
| dc.contributor.author | Visser, Adele | |
| dc.contributor.author | Hoosen, Anwar Ahmed | |
| dc.date.accessioned | 2011-08-03T06:29:51Z | |
| dc.date.available | 2011-08-03T06:29:51Z | |
| dc.date.issued | 2011-05 | |
| dc.description.abstract | The WHO advocates introduction of routine HPV vaccination as part of a national EPI programme provided HPV prevention is considered a health priority, and the programme is logistically feasible and financially sustainable. High vaccine costs are often cited as barriers to national public health usage. However, a recent study in Cape Town showed a cost benefit for routine HPV vaccination use. Cervical cancer screening programmes should continue, as genotypes not included in the vaccines may still cause malignant transformation. | en_US |
| dc.description.uri | http://www.cmej.org.za/index.php/cmej | en_US |
| dc.identifier.citation | Viser, A & Hoosen, A 2011, 'More about... medical virology : Human papillomavirus (HPV)', CME : Continuing Medical Education, vol. 29, no. 5, pp. 214. | en_US |
| dc.identifier.issn | 1016-6742 (print) | |
| dc.identifier.issn | 2078-5143 (online) | |
| dc.identifier.uri | http://hdl.handle.net/2263/16984 | |
| dc.language.iso | en | en_US |
| dc.publisher | Health and Medical Publishing Group | en_US |
| dc.rights | Health and Medical Publishing Group | en_US |
| dc.subject | Human papillomavirus vaccine | en_US |
| dc.title | More about... medical virology : Human papillomavirus (HPV) | en_US |
| dc.type | Article | en_US |